These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26944099)

  • 1. PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody-antigen binding model.
    Haraya K; Tachibana T; Iwayanagi Y; Maeda A; Ozeki K; Nezu J; Ishigai M; Igawa T
    Drug Metab Pharmacokinet; 2016 Apr; 31(2):123-32. PubMed ID: 26944099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered monoclonal antibody with novel antigen-sweeping activity in vivo.
    Igawa T; Maeda A; Haraya K; Tachibana T; Iwayanagi Y; Mimoto F; Higuchi Y; Ishii S; Tamba S; Hironiwa N; Nagano K; Wakabayashi T; Tsunoda H; Hattori K
    PLoS One; 2013; 8(5):e63236. PubMed ID: 23667591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation.
    Igawa T; Haraya K; Hattori K
    Immunol Rev; 2016 Mar; 270(1):132-51. PubMed ID: 26864109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn.
    Yang D; Giragossian C; Castellano S; Lasaro M; Xiao H; Saraf H; Hess Kenny C; Rybina I; Huang ZF; Ahlberg J; Bigwarfe T; Myzithras M; Waltz E; Roberts S; Kroe-Barrett R; Singh S
    MAbs; 2017 Oct; 9(7):1105-1117. PubMed ID: 28786732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
    Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
    Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
    Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
    MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering.
    Hori Y; Ohmine K; Katada H; Noguchi Y; Sato K; Nambu T; Adeline LR; Wan GS; Haraya K; Ozeki K; Nanami M; Tachibana T; Sampei Z; Kuramochi T; Nezu J; Hattori K; Igawa T
    MAbs; 2022; 14(1):2068213. PubMed ID: 35482905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics.
    Devanaboyina SC; Lynch SM; Ober RJ; Ram S; Kim D; Puig-Canto A; Breen S; Kasturirangan S; Fowler S; Peng L; Zhong H; Jermutus L; Wu H; Webster C; Ward ES; Gao C
    MAbs; 2013; 5(6):851-9. PubMed ID: 24492341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered pH-dependent recycling antibodies enhance elimination of Staphylococcal enterotoxin B superantigen in mice.
    Kroetsch A; Qiao C; Heavey M; Guo L; Shah DK; Park S
    MAbs; 2019; 11(2):411-421. PubMed ID: 30526311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.
    Sampei Z; Haraya K; Tachibana T; Fukuzawa T; Shida-Kawazoe M; Gan SW; Shimizu Y; Ruike Y; Feng S; Kuramochi T; Muraoka M; Kitazawa T; Kawabe Y; Igawa T; Hattori K; Nezu J
    PLoS One; 2018; 13(12):e0209509. PubMed ID: 30592762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between the structural conformation of monoclonal antibody layers and antigen binding capacity.
    Xu H; Zhao X; Lu JR; Williams DE
    Biomacromolecules; 2007 Aug; 8(8):2422-8. PubMed ID: 17616226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid depletion of "catch-and-release" anti-ASGR1 antibody in vivo.
    Devanaboyina SC; Li P; LaGory EL; Poon-Andersen C; Cook KD; Soto M; Wang Z; Dang K; Uyeda C; Case RB; Thomas VA; Primack R; Ponce M; Di M; Ouyang B; Kaner J; Lam SK; Mostafavi M
    MAbs; 2024; 16(1):2383013. PubMed ID: 39051531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
    Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
    Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies.
    Yuan D; Rode F; Cao Y
    Eur J Pharm Sci; 2019 Oct; 138():105032. PubMed ID: 31394258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action.
    Sheridan D; Yu ZX; Zhang Y; Patel R; Sun F; Lasaro MA; Bouchard K; Andrien B; Marozsan A; Wang Y; Tamburini P
    PLoS One; 2018; 13(4):e0195909. PubMed ID: 29649283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
    Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
    Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization.
    Igawa T; Ishii S; Tachibana T; Maeda A; Higuchi Y; Shimaoka S; Moriyama C; Watanabe T; Takubo R; Doi Y; Wakabayashi T; Hayasaka A; Kadono S; Miyazaki T; Haraya K; Sekimori Y; Kojima T; Nabuchi Y; Aso Y; Kawabe Y; Hattori K
    Nat Biotechnol; 2010 Nov; 28(11):1203-7. PubMed ID: 20953198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.
    Zheng Y; Scheerens H; Davis JC; Deng R; Fischer SK; Woods C; Fielder PJ; Stefanich EG
    Clin Pharmacol Ther; 2011 Feb; 89(2):283-90. PubMed ID: 21191378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.
    Li B; Tesar D; Boswell CA; Cahaya HS; Wong A; Zhang J; Meng YG; Eigenbrot C; Pantua H; Diao J; Kapadia SB; Deng R; Kelley RF
    MAbs; 2014; 6(5):1255-64. PubMed ID: 25517310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.